In a statement, the Drug Regulatory Authority of Pakistan (DRAP) said the health authorities in Punjab, the most populous province, had launched the investigation into the drug Avastin, which is licensed for use in Pakistan.
Tag Archive for: Avastin
The FDA on Wednesday rejected Outlook Therapeutics’ investigational ophthalmic bevacizumab solution ONS-5010, which the company was proposing as a treatment for wet age-related macular degeneration.
The regulator Wednesday approved expanding Lonsurf’s label for previously treated metastatic colorectal cancer, authorizing a combination regimen with Roche’s bevacizumab.
Swiss drugmaker Roche Holding AG plans to sell its 800-employee drug manufacturing plant in Vacaville, California, or it will shut the factory by 2029, according to e-mailed letters to workers seen by Reuters on Wednesday.
The combination treatment of AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) met its primary endpoint in the Phase III DUO-O trial in advanced high-grade epithelial ovarian cancer, according to an interim analysis of the study released Wednesday.
G1 Therapeutics Inc. said on Monday it would terminate a late-stage study of its lead drug as it was unlikely to be effective in extending survival in patients with a type of colorectal cancer, sending its shares plunging more than 50%.
According to data from the IMbrave150 study, the drug combo is the first treatment option in over a decade to confer significant overall survival benefit over standard of care in unresectable hepatocellular carcinoma.
Following a development setback, MEI Pharma will pivot toward two earlier clinical-stage assets and cut 30% of its workforce in a strategic realignment, the company announced Monday.
A strong product pipeline and increased group sales confirm that Roche is on the right growth path.
Shares of Regulus Therapeutics plunged nearly 10% Monday after the company disclosed that its partner Sanofi has terminated a development agreement for a small RNA molecule inhibitor being developed for Alport syndrome. And on Monday, pharma giant Merck announced it has halted the Phase III LYNK-003 trial evaluating PARP inhibitor Lynparza for patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction.
